The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab
- 34 Downloads
Crevicular fluid was used to assess interleukin-17 (IL-17) and vascular endothelial growth factor (VEGF) in cancer patients receiving zoledronic acid and/or bevacizumab. The markers were also assessed in the serum.
Twenty-five patients were included and comprised three groups: patients who received zoledronic acid (n = 9), patients who received bevacizumab (n = 9), and patients who received zoledronic acid combined with bevacizumab (n = 5). One patient received zoledronic acid and everolimus and another received zoledronic acid, bevacizumab, and temsirolimus. IL-17 and VEGF were measured by standard quantitative ELISA kits and assessed in two study points.
Twenty-four patients maintained good periodontal health; one had asymptomatic osteonecrosis of the jaw. First assessment: 44 samples were collected; 21 from serum and 23 from crevicular fluid. Second assessment, 6 months later: 11 samples were collected; 6 from serum and 5 from crevicular fluid. IL-17 was detected in all samples, in serum and crevicular fluid, and remained unchanged at both time points. Serum VEGF in patients with bevacizumab alone or combined with zoledronic acid was significantly lower compared with that of patients who received zoledronic acid alone. VEGF was not detected in the crevicular fluid.
Crevicular fluid might be an easy, non-invasive means to assess IL-17. The stable values of IL-17 in crevicular fluid and serum and the lack of VEGF in the crevicular fluid could be related to the good periodontal health of our patients. Further studies are needed to assess IL-17 and VEGF in the crevicular fluid in patients with and without periodontal disease.
KeywordsCrevicular fluid Interleukin-17 Bevacizumab mTOR inhibitors VEGF Zoledronic acid
Compliance with ethical standards
They were all informed about the study and signed a detailed informed consent form. Ethical approval for the study was obtained by the Committee of Research and Ethics of the Dental School, National and Kapodistrian University of Athens.
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H (2006) Th17 functions as an osteoclastogenic helper T cell subject that links T cell activation and bone destruction. J Exp Med 27(203):2673–2682. https://doi.org/10.1084/jem.20061775 CrossRefGoogle Scholar
- 4.Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird BA, Lee CS, Shnier R, Portek IJ (2006) Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 54:1122–1131. https://doi.org/10.1002/art.21749 CrossRefGoogle Scholar
- 7.Nicolatou-Galitis O, Razis E, Galiti D, Galitis E, Labropoulos S, Tsimpidakis A, Sgouros J, Karampeazis A, Migliorati C (2015) Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving aniresorptives alone or combined with targeted therapies: report of 5 cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 120:699–706. https://doi.org/10.1016/j.oooo.2015.08.007 CrossRefGoogle Scholar
- 16.Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y, Chen C, Chen WJ, Wang S, le AD, Shi S (2010) Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res 25:1668–1679. https://doi.org/10.1002/jbmr.37 CrossRefGoogle Scholar
- 19.Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayianni A, Kyrtsonis MC, Repousis P, Barbounis V, Migliorati CA (2011) Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:195–202. https://doi.org/10.1016/j.tripleo.2011.02.037 CrossRefGoogle Scholar
- 20.Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120. https://doi.org/10.1093/annonc/mdn554 CrossRefGoogle Scholar
- 21.Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145. https://doi.org/10.1093/annonc/mdn526 CrossRefGoogle Scholar
- 22.Vladau M, Cimpean AM, Balica RA, Jitariu AA, Popovici RA, Raica M (2016) VEGF/VEGFR2 Axis in periodontal disease progression and angiogenesis: basic approach for a new therapeutic strategy. In Vivo 30:53–60Google Scholar
- 23.Padma R, Anaji S, Indeevar P, Indranil S, Chetan SK (2014) Vascular endothelial growth factor levels in gingival crevicular fluid before and after periodontal therapy. J Clin Diagn Res 8:75–79Google Scholar
- 25.Santini D, Vincenzi B, Battistoni F et al (2007) In vivo perspective study about the effects of weekly low dose administration of zoledronic acid (ZA) on angiogenesis. J Clin Oncol 25(suppl):152Google Scholar
- 26.Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G (2003) ZA induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893–2897Google Scholar
- 28.Thumbigere-Math V, Michalowicz B, Hughes PJ, Basi DL et al (2016) Serum markers of bone turnover and angiogenesis in bisphosphonate-related osteonecrosis of the jaw patients following discontinuation of long-term intravenous bisphosphonate therapy. J Oral Maxillofac Surg 74(4):738–746. https://doi.org/10.1016/j.joms.2015.09.028 CrossRefGoogle Scholar